Lifitegrast: all 25 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal MicroscopyNot yet recruitingNCT07560735Phase 4
• This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry EyeNot yet recruitingNCT07490535Phase 4
• Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens WearersCompletedNCT05505292Phase 4Results posted
• The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens WearersCompletedNCT04297618Phase 4Results posted
• A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)CompletedNCT02284516Phase 3Results posted
• A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry EyeCompletedNCT01743729Phase 3Results posted
• Safety Study of Lifitegrast to Treat Dry EyeCompletedNCT01636206Phase 3Results posted
• Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)CompletedNCT01421498Phase 3Results posted
• A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)CompletedNCT00926185Phase 2Results posted
• Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic ConjunctivitisCompletedNCT00882687Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseCompletedNCT07128628Phase 2
• A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye DiseaseWithdrawnNCT07111013Phase 3
• Lifitegrast Eye Drops in Healthy Subjects：Phase I StudyCompletedNCT07040826Phase 1
• A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory TreatmentCompletedNCT07025811Phase 4
• Treatment Regimens in Meibomian Gland DysfunctionCompletedNCT05594745Phase 4
• Efficacy of Xiidra in Dry Eye Disease After Collagen Cross LinkingStatus unknownNCT05045053Phase 4
• The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host DiseaseCompletedNCT04792580Early Phase 1
• The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) StudyCompletedNCT04669561Phase 4
• Ocular Inflammation in Cataract Patients and Response to Treatment With XiidraWithdrawnNCT04120987Phase 4
• Effect of Lifitegrast 5% on Tear Film MarkersWithdrawnNCT03952481Phase 4
• Lifitegrast 5% Ophthalmic Solution and Contact Lens DrynessCompletedNCT03686878Phase 4
• Effect of Lifitegrast on Dry Eye Disease Signs and SymptomsCompletedNCT03451396Phase 4
• Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens WearersWithdrawnNCT03431272Phase 4
• Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye DiseaseWithdrawnNCT03408015Phase 4
• SAR 1118 in Human Subjects Undergoing Pars Plana VitrectomyTerminatedNCT00936520Phase 1

← Lifitegrast overview